Avalo Therapeutics (AVTX) Shares Outstanding (Weighted Average) (2014 - 2026)
Avalo Therapeutics posted quarterly Shares Outstanding (Weighted Average) of $20.1 million for Q1 2026, up 91.22% year-on-year from $10.5 million in Q1 2025, and up 50.0% on a QoQ basis from $13.4 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Shares Outstanding (Weighted Average) data on file, last reported at $20.1 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 91.22% year-over-year to $20.1 million; the trailing twelve-month figure through Mar 2026 stood at $20.1 million (up 91.22% YoY), and the FY2025 full-year result was $13.4 million, up 202.86% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $20.1 million, up from $13.4 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $20.1 million in Q1 2026 and bottomed at $39202.0 in Q4 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $5.5 million (2024), against an average of $6.3 million.
- The widest annual swing landed in 2023, when Shares Outstanding (Weighted Average) tumbled 99.48%; it then jumped 2746.41% in 2024.
- A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $39202.0 in 2022, then jumped by 608.45% to $277727.0 in 2023, then surged by 1493.7% to $4.4 million in 2024, then soared by 202.86% to $13.4 million in 2025, then jumped by 50.0% to $20.1 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $20.1 million (Q1 2026), $13.4 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | 20.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.11 Mn |
| Dec 31, 2025 | 13.40 Mn |
| Sep 30, 2025 | 11.80 Mn |
| Jun 30, 2025 | 10.67 Mn |
| Mar 31, 2025 | 10.51 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 5.55 Mn |
| Jun 30, 2024 | 946,756.00 |
| Mar 31, 2024 | 859,381.00 |
| Dec 31, 2023 | 277,727.00 |
| Sep 30, 2023 | 194,851.00 |
| Jun 30, 2023 | 58,217.00 |
| Mar 31, 2023 | 48,845.00 |
| Dec 31, 2022 | 39,202.00 |
| Sep 30, 2022 | 9.40 Mn |
| Jun 30, 2022 | 9.40 Mn |
| Mar 31, 2022 | 9.40 Mn |
| Dec 31, 2021 | 361,644.00 |
| Sep 30, 2021 | 8.37 Mn |
| Jun 30, 2021 | 7.70 Mn |
| Mar 31, 2021 | 88.58 Mn |
| Dec 31, 2020 | 66.69 Mn |
| Sep 30, 2020 | 74.90 Mn |
| Jun 30, 2020 | 58.37 Mn |
| Mar 31, 2020 | 1.66 Mn |
| Dec 31, 2019 | 2.86 Mn |
| Sep 30, 2019 | 2.86 Mn |
| Jun 30, 2019 | 42.05 Mn |
| Mar 31, 2019 | 2.86 Mn |
| Dec 31, 2018 | 34.77 Mn |
| Sep 30, 2018 | 32.75 Mn |
| Jun 30, 2018 | 31.78 Mn |
| Mar 31, 2018 | 31.32 Mn |
| Dec 31, 2017 | 18.41 Mn |
| Sep 30, 2017 | 21.38 Mn |
| Jun 30, 2017 | 13.27 Mn |
| Mar 31, 2017 | 10.22 Mn |
| Dec 31, 2016 | 8.83 Mn |
| Sep 30, 2016 | 8.69 Mn |
| Jun 30, 2016 | 8.65 Mn |
| Mar 31, 2016 | 8.65 Mn |
| Dec 31, 2015 | 2.23 Mn |
| Sep 30, 2015 | 649,721.00 |
| Jun 30, 2015 | 649,721.00 |
| Mar 31, 2015 | 649,721.00 |
| Dec 31, 2014 | 642,052.00 |
| Sep 30, 2014 | 646,863.00 |